At Week 40 in the Phase 3 VELA program for moderate-to-severe hidradenitis suppurativa (HS), sonelokimab achieved a 62% HiSCR75 response and up to 32% HiSCR100, with up to 77% reaching IHS4-55 and up to 25% meeting an inflammatory remission composite (A100+N100+DT100). Patient-reported outcomes tracked with lesion control: HiSQOL improved by roughly 12 points from baseline, 43% achieved at least a 3-point reduction in worst skin pain NRS (baseline ≥3), and 65% saw at least a 4-point DLQI improvement (baseline ≥4). No new safety signals were observed.
MoonLake Immunotherapeutics released long-term data from its identically designed, registrational VELA-1 and VELA-2 trials (n=838) ahead of a late-breaking AAD presentation. Both studies used the higher HiSCR75 threshold as the primary endpoint at Week 16, after which placebo patients crossed over to active treatment and all participants continued on monthly 120 mg maintenance through Week 52. Discontinuations were reported at the low end relative to other pivotal HS programs. The company argues the 40-week data position sonelokimab’s lesion control at or above what’s been reported at one year for approved IL-17A and IL‑17A/F agents, though cross-trial comparisons are inherently constrained.
Strategically, the readout underscores a bet on durability, higher clinical thresholds, and quality-of-life outcomes to differentiate in an increasingly crowded IL-17 HS market. That positioning matters because the Week 16 picture was mixed: VELA-1 met all primary and key secondary endpoints; VELA-2 narrowly missed significance on the composite estimand due to intercurrent events, despite supportive results under an alternate treatment policy strategy. The Week 40 trajectory and breadth of PRO gains aim to reframe the narrative around long-term disease control rather than a single time point, while highlighting consistency between the two trials. It also reflects an anticipatory alignment with regulators who have been pressing for higher bar endpoints (HiSCR75/100), tunnel resolution metrics, and patient-relevant benefits.
For sites, the program reinforces the operational premium on standardized lesion, nodule, and draining tunnel assessments, coupled with intensive ePRO capture. The crossover design post-Week 16 likely supported retention and reduced discontinuations, but it also eliminates a long-term comparator, pushing sites and CROs to sustain data quality in an “all-active” phase where bias and protocol deviations can creep in. Sponsors will see the VELA estimand experience as a case study in proactively managing intercurrent events in inflammatory disease trials, where background therapies, procedures, and rescue use can dilute signals under composite strategies. For payers and health technology bodies, the combination of higher-threshold responses, IHS4-55, and sizable improvements in pain and daily function may strengthen value arguments if replicated at one year. Patients stand to benefit from monthly subcutaneous dosing and a credible signal of continued improvement through 40 weeks.
The next inflection arrives with 52-week data in Q2 2026 and a planned HS BLA filing in the second half of the year. Watch for maintenance of HiSCR100 and inflammatory remission rates, stability of safety—particularly class-typical mucocutaneous events—and adjudicated tunnel outcomes. Regulators may scrutinize the VELA-2 estimand miss at Week 16 and the reliance on as-observed analyses after crossover; the completeness of sensitivity analyses could become pivotal. Commercially, the question is whether durability and PRO depth can pry share from established IL-17 agents that already have HS labels, and how MoonLake will leverage its broader IL‑17 portfolio momentum with upcoming PsA Phase 3 readouts and an adolescent HS program. Execution now hinges on locking in 52-week durability, converting the estimand narrative into regulatory comfort, and preparing for head-to-head or pragmatic data demands likely to come post-approval.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
